WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported third-quarter and year-to-date 2007 financial results. For the third quarter, net sales from continuing operations increased 18.6% to $314.0 million from $264.7 million in the third quarter of 2006. Both the Research Models and Services (RMS) and Preclinical Services (PCS) business segments reported strong net sales growth, as pharmaceutical and biotechnology companies continued to invest in basic research and increased their strategic use of outsourced drug development services. Foreign exchange contributed 2.6% to the net sales growth.
